Table 2. Historical Immunologic and Virologic Characteristics of HIV/SARS-CoV-2 Co-Infected Patients.
| Hospitalized (n)(%) |
Not Hospitalized
(n)(%) |
p-Value | |
|---|---|---|---|
| Total (n) | 24 | 81 | |
| Sex, biologic | |||
| Male | 17 (70.8) | 54 (66.7) | 0.893 |
| Race | 0.265 | ||
| Black | 19 (79.2) | 47 (58.0) | |
| White | 4 (16.7) | 22 (27.2) | |
| Hispanic | 1 (4.2) | 9 (11.1) | |
| Other | 0 (0.0) | 3 (3.7) | |
| Mean Age (years) (SD) | 59.0 (11.3) | 47.6 (11.7) | <0.001 |
| Age Range | 0.006 | ||
| 18-24 years old | 0 (0.0) | 1 (1.2) | |
| 25-40 years old | 2 (8.3) | 20 (24.7) | |
| 41-50 years old | 2 (8.3) | 21 (25.9) | |
| 51-60 years old | 9 (37.5) | 28 (34.6) | |
| >60 years old | 11 (45.8) | 11 (13.6) | |
| Insurance | 0.022 | ||
| None | 0 (0.0) | 3 (3.7) | |
| Private | 4 (17.4) | 37 (45.7) | |
| Public | 19 (82.6) | 41 (50.6) | |
| ART Class a | 0.646 | ||
| INSTI | 14 (63.6) | 61 (78.2) | |
| INSTI + NNRTI | 2 (9.1) | 4 (5.1) | |
| INSTI + PI | 1 (4.5) | 5 (6.4) | |
| INSTI + PI + NNRTI | 1 (4.5) | 1 (1.3) | |
| NNRTI | 1 (4.5) | 2 (2.6) | |
| PI | 3 (13.6) | 4 (5.1) | |
| PI + EI b | 0 (0.0) | 1 (1.3) | |
| Years Living With HIV (mean)(SD) | 15.8 (8.7) | 12.6 (9.4) | 0.165 |
| HIV Viral Load Range | 0.037 | ||
| <200 (copies/mL) | 19 (82.6) | 74 (91.4) | |
| 200-1000 (copies/mL) | 0 (0.0) | 1 (1.2) | |
| >1000 (copies/mL) | 0 (0.0) | 4 (4.9) | |
| >5000 (copies/mL) | 4 (17.4) | 2 (2.5) | |
| Mean CD4 Count (SD) | 444.3 (243.8) | 578.6 (254.6) | 0.026 |
| CD4 Count ≤ 200 cells/mm3 | 4 (17.4) | 6 (7.4) | 0.302 |
| CD4 Count Nadir Range (cells/mm3) | 0.053 | ||
| <50 cells/mm3 | 7 (29.2) | 13 (16.0) | |
| 51-100 cells/mm3 | 5 (20.8) | 6 (7.4) | |
| 101-200 cells/mm3 | 5 (20.8) | 13 (16.0) | |
| >200 cells/mm3 | 3 (12.5) | 32 (39.5) | |
| CD4 Count Nadir ≤200 cells/mm3 | 17 (70.8) | 32 (39.5) | 0.014 |
| AIDS-Defined | 20 (87.0) | 47 (61.0) | 0.039 |
| ART Resistance c | 10 (50.0) | 22 (34.9) | 0.345 |
| Hepatitis B Infection | 0.417 | ||
| Chronic Hepatitis B Infection | 3 (12.5) | 5 (6.2) | |
| Resolved Hepatitis B Infection d | 2 (8.3) | 13 (16.0) | |
| Hepatitis C Infection = | 0.128 | ||
| Chronic Hepatitis C Infection | 2 (8.3) | 2 (2.5) | |
| Treatment with Cure | 4 (16.7) | 5 (6.2) | |
| Spontaneous Clearance | 3 (12.5) | 6 (7.4) | |
| Comorbidities | |||
| BMI (mean (SD)) | 30.6 (8.2) | 31.6 (8.1) | 0.609 |
| Cardiovascular Disease (%) | 14 (58.3) | 8 (9.9) | <0.001 |
| Diabetes (%) | 10 (41.7) | 11 (13.6) | 0.006 |
| Hypertension (%) | 17 (70.8) | 36 (44.4) | 0.041 |
| Dyslipidemia (%) | 14 (58.3) | 37 (45.7) | 0.391 |
| Chronic Kidney Disease (%) | 10 (41.7) | 6 (7.4) | <0.001 |
| Chronic Lung Disease (%) | 7 (29.2) | 17 (21.0) | 0.575 |
| Cirrhosis (%) | 5 (20.8) | 2 (2.5) | 0.007 |
Note: a = in addition to NRTI backbone (F/TAF in vast majority of patients); b = entry inhibitor, i.e. maraviroc; c = defined as clinically significant resistance to ART in one or more drug class; d = either isolated anti-HBc (with negative HBV DNA) or anti-HBc + anti-HBs